NO308984B1 - Farmasøytisk bærersystem inneholdende definerte lipider, samt preparat av samme - Google Patents
Farmasøytisk bærersystem inneholdende definerte lipider, samt preparat av samme Download PDFInfo
- Publication number
- NO308984B1 NO308984B1 NO943543A NO943543A NO308984B1 NO 308984 B1 NO308984 B1 NO 308984B1 NO 943543 A NO943543 A NO 943543A NO 943543 A NO943543 A NO 943543A NO 308984 B1 NO308984 B1 NO 308984B1
- Authority
- NO
- Norway
- Prior art keywords
- lipid
- carrier system
- polar
- mixture
- amphiphatic
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 105
- 238000002360 preparation method Methods 0.000 title claims description 13
- 239000003937 drug carrier Substances 0.000 title 1
- 210000004400 mucous membrane Anatomy 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 9
- 239000000654 additive Substances 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 69
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 18
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 15
- 230000000975 bioactive effect Effects 0.000 claims description 15
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 15
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 229960004194 lidocaine Drugs 0.000 claims description 9
- 239000003589 local anesthetic agent Substances 0.000 claims description 8
- 239000011159 matrix material Substances 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 150000003904 phospholipids Chemical class 0.000 claims description 7
- 239000012736 aqueous medium Substances 0.000 claims description 6
- 206010052428 Wound Diseases 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 150000003626 triacylglycerols Chemical class 0.000 claims description 5
- 229930186217 Glycolipid Natural products 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 claims description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 claims 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims 1
- 229940049918 linoleate Drugs 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 abstract description 6
- 238000009472 formulation Methods 0.000 description 39
- 239000000463 material Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 208000012266 Needlestick injury Diseases 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 125000005456 glyceride group Chemical group 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000008240 homogeneous mixture Substances 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000008347 soybean phospholipid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 210000005178 buccal mucosa Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- -1 mono- Chemical class 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- XOMRRQXKHMYMOC-NRFANRHFSA-N (3s)-3-hexadecanoyloxy-4-(trimethylazaniumyl)butanoate Chemical group CCCCCCCCCCCCCCCC(=O)O[C@@H](CC([O-])=O)C[N+](C)(C)C XOMRRQXKHMYMOC-NRFANRHFSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 239000012612 commercial material Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9200952A SE9200952D0 (sv) | 1992-03-27 | 1992-03-27 | Pharmaceutical carrier system containing defined lipids |
| PCT/SE1993/000257 WO1993019736A1 (en) | 1992-03-27 | 1993-03-26 | A pharmaceutical carrier system containing defined lipids |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO943543L NO943543L (no) | 1994-09-23 |
| NO943543D0 NO943543D0 (no) | 1994-09-23 |
| NO308984B1 true NO308984B1 (no) | 2000-11-27 |
Family
ID=20385758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO943543A NO308984B1 (no) | 1992-03-27 | 1994-09-23 | Farmasøytisk bærersystem inneholdende definerte lipider, samt preparat av samme |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5635205A (sv) |
| EP (1) | EP0636020B1 (sv) |
| JP (1) | JPH07508708A (sv) |
| AT (1) | ATE179885T1 (sv) |
| DE (1) | DE69324914T2 (sv) |
| DK (1) | DK0636020T3 (sv) |
| FI (1) | FI114140B (sv) |
| NO (1) | NO308984B1 (sv) |
| SE (1) | SE9200952D0 (sv) |
| WO (1) | WO1993019736A1 (sv) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665379A (en) * | 1990-09-28 | 1997-09-09 | Pharmacia & Upjohn Aktiebolag | Lipid particle forming matrix, preparation and use thereof |
| SE9402453D0 (sv) * | 1994-07-12 | 1994-07-12 | Astra Ab | New pharmaceutical preparation |
| DE4447287C1 (de) * | 1994-12-30 | 1996-11-07 | Cevc Gregor | Präparat zum Wirkstofftransport durch Barrieren |
| DE69511418T2 (de) * | 1995-10-28 | 2000-03-30 | Braun Melsungen Ag | Lokalanästhetika und/oder Zentralanalgetika enthaltende pharmazeutische Zusammensetzungen |
| WO1998047487A1 (en) * | 1997-04-17 | 1998-10-29 | Dumex-Alpharma A/S | A novel bioadhesive drug delivery system based on liquid crystals |
| ATE535232T1 (de) | 1997-09-18 | 2011-12-15 | Pacira Pharmaceuticals Inc | Retardierte freisetzung liposomaler anesthetischer zusammensetzungen |
| IL135989A0 (en) | 1997-11-14 | 2001-05-20 | Skyepharma Inc | Processes for the production of multivesicular liposomes |
| US6277413B1 (en) | 1998-07-17 | 2001-08-21 | Skyepharma, Inc. | Biodegradable compositions for the controlled release of encapsulated substances |
| KR100638150B1 (ko) | 1998-12-23 | 2006-10-26 | 이데아 악티엔게젤샤프트 | 생체내에서 국부적인 비침습성 용도로 사용되는 개선된 제제 |
| SE0000730D0 (sv) * | 2000-03-06 | 2000-03-06 | Scotia Holdings Plc | Lipid carrier |
| EP1395243A2 (en) * | 2001-05-31 | 2004-03-10 | SkyePharma Inc. | Encapsulation of nanosuspensions in liposomes and microspheres |
| US8920843B2 (en) * | 2007-11-07 | 2014-12-30 | Svip5 Llc | Slow release of organic salts of local anesthetics for pain relief |
| CN102892408A (zh) * | 2010-04-01 | 2013-01-23 | 帕玛内斯特公司 | 适于局部麻醉剂的无水药物组合物 |
| IN2014MN02213A (sv) | 2012-05-10 | 2015-07-10 | Painreform Ltd | |
| US10220093B2 (en) | 2013-02-28 | 2019-03-05 | Mira Pharma Corporation | Long-acting semi-solid lipid formulations |
| CA2903020C (en) | 2013-02-28 | 2019-06-18 | Mira Pharma Corporation | Injectable long-acting local anesthetic semi-solid formulations and its compostions |
| US10561606B2 (en) | 2017-12-06 | 2020-02-18 | Mira Pharma Corporation | Injectable long-acting local anesthetic semi-solid gel formulations |
| US11426418B2 (en) | 2017-12-06 | 2022-08-30 | Mira Pharma Corporation | Injectable long-acting semi-solid gel formulations |
| US11033495B1 (en) | 2021-01-22 | 2021-06-15 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US11278494B1 (en) | 2021-01-22 | 2022-03-22 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
| US11357727B1 (en) | 2021-01-22 | 2022-06-14 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3585967D1 (de) * | 1984-03-08 | 1992-06-11 | Phares Pharma Holland | Liposombildende zusammensetzung. |
| GB8613811D0 (en) * | 1986-06-06 | 1986-07-09 | Phares Pharm Res Nv | Composition & method |
| US5059421A (en) * | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
| SE9003100D0 (sv) * | 1990-09-28 | 1990-09-28 | Kabivitrum Ab | Lipid formulation system |
-
1992
- 1992-03-27 SE SE9200952A patent/SE9200952D0/sv unknown
-
1993
- 1993-03-26 DK DK93908232T patent/DK0636020T3/da active
- 1993-03-26 EP EP93908232A patent/EP0636020B1/en not_active Expired - Lifetime
- 1993-03-26 WO PCT/SE1993/000257 patent/WO1993019736A1/en active IP Right Grant
- 1993-03-26 AT AT93908232T patent/ATE179885T1/de not_active IP Right Cessation
- 1993-03-26 DE DE69324914T patent/DE69324914T2/de not_active Expired - Fee Related
- 1993-03-26 US US08/307,761 patent/US5635205A/en not_active Expired - Fee Related
- 1993-03-26 JP JP5517360A patent/JPH07508708A/ja active Pending
-
1994
- 1994-09-23 NO NO943543A patent/NO308984B1/no not_active IP Right Cessation
- 1994-09-26 FI FI944441A patent/FI114140B/sv not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0636020A1 (en) | 1995-02-01 |
| DE69324914D1 (de) | 1999-06-17 |
| SE9200952D0 (sv) | 1992-03-27 |
| FI944441A0 (sv) | 1994-09-26 |
| US5635205A (en) | 1997-06-03 |
| DE69324914T2 (de) | 1999-12-09 |
| NO943543L (no) | 1994-09-23 |
| NO943543D0 (no) | 1994-09-23 |
| ATE179885T1 (de) | 1999-05-15 |
| EP0636020B1 (en) | 1999-05-12 |
| DK0636020T3 (da) | 1999-11-15 |
| JPH07508708A (ja) | 1995-09-28 |
| FI114140B (sv) | 2004-08-31 |
| WO1993019736A1 (en) | 1993-10-14 |
| FI944441A (sv) | 1994-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO308984B1 (no) | Farmasøytisk bærersystem inneholdende definerte lipider, samt preparat av samme | |
| US5665379A (en) | Lipid particle forming matrix, preparation and use thereof | |
| KR100399522B1 (ko) | 통증제어용신규제약제제 | |
| EP0153926B2 (en) | Microdroplets of water-insoluble drugs | |
| US20020048596A1 (en) | Preparation for the transport of an active substance across barriers | |
| EP0514506B1 (en) | Lipid formulation system | |
| JPH09508414A (ja) | 二重層製剤 | |
| HU219240B (en) | A pharmaceutical composition containing lipid system and heparine, and process for its production | |
| JPH04505319A (ja) | 創傷、切傷および擦傷に対する治療剤のデリバリーとしてのリポソームの使用 | |
| DE4447287C1 (de) | Präparat zum Wirkstofftransport durch Barrieren | |
| CA2375371A1 (en) | Oil-core compositions for the sustained release of hydrophobic drugs | |
| CA3018670A1 (en) | Viscoelastic gel of liraglutide adapted for once-weekly or once bi-weekly administration | |
| CN112190504B (zh) | 一种含有玫瑰精油的长效液体凝胶及其制备方法和应用 | |
| JPH01165523A (ja) | ネドクロミルナトリウム組成物およびその調製方法 | |
| JPS63500456A (ja) | 薬剤に用いるミクロエマルジョン | |
| PL197939B1 (pl) | Liposomowy preparat zawierający przeciwnowotworową substancję aktywną, sposób jego wytwarzania i zawierająca go kompozycja farmaceutyczna |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |